This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...

A composition comprising a novel Ca<2+>-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited...

A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecifi c cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenin e nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel i s activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibite...

A composition comprising a novel Ca<2+>-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited...

PURPOSE: A new therapeutic agent composition for diabetes containing one or more compounds selected from SJ-2030 and SJ-2031 separated from Carduus crispus L. and isoliovil as an effective ingredient is provided. These compounds exhibit excellent blood-glucose lowering actions in efficacy tests and higher safety than other drugs(tolbutamide) during oral or peritoneal administration in acute toxicity tests. CONSTITUTION: The diabetes therapeutic composition contains (7R, 8R, 8'R, 9'R)-4, 7, 4', 9...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 2-12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue) to a mammal in need thereof. 2...

This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal with positive effect by glycemic control without observable unfavourable effects which method comprises administering 2 to 12 mg daily 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione (Compound I) or a pharmaceutically acceptable salt thereof and sulfonyl urea. 2. A method according to Claim 1 wherein the c is glibenclamide glipizide gliclazide glimepiride tola...

1. A use of an insulin sensitiser an insulin secretagogue and a biguanide antihyperglycaemic agent as a pharmaceutically acceptable carrier therefor for use as an active therapeutic substance for treating diabetes mellitus and conditions associated with diabetes mellitus wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2.4-dione (Compound I) which comprises the administration of 2 to 12 mg of said Compound. 2. The use according to claim 1 wherein ...

A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser;5-[4-[2-N(N-methyl-(2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-2,4-dione and an insulin secretagogue, to a mammal in need thereof.